WallStSmart
ZBIO

Zenas BioPharma, Inc. Common Stock

NASDAQ: ZBIO · HEALTHCARE · BIOTECHNOLOGY

$20.40
-4.95% today

Updated 2026-06-05

Market cap
$1.16B
P/E ratio
P/S ratio
119.50x
EPS (TTM)
$-9.10
Dividend yield
52W range
$9 – $45
Volume
0.7M

Zenas BioPharma, Inc. Common Stock (ZBIO) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-18.3%
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
-82.5%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+2.4%
Last 4 reports
Positive reaction rate
50%
2 of 4 quarters
Largest single-day move
+12.1%
2025-08-12
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-05-13$-1.46+5.2%$19.16$18.90-1.4%
2026-03-16$-1.39-16.8%$24.04$23.48-2.3%
2025-11-12$-1.22-43.5%$35.20$35.66+1.3%
2025-08-12$-1.25-17.9%$14.91$16.71+12.1%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2026-03-31$-1.54$-1.46+5.2%
2025-12-31$-1.19$-1.39-16.8%$10.00M+100.0%
2025-09-30$-0.85$-1.22-43.5%
2025-06-30$-1.06$-1.25-17.9%
2025-03-31$-1.03$-0.80+22.3%$10.00M
2024-12-31$-1.02$-1.26-23.7%$5.00M
2024-09-30$-9.30$-5.02+46.0%
2024-06-30$-1.24$-2.79-125.0%

Frequently asked questions

Has Zenas BioPharma, Inc. Common Stock beaten earnings estimates?

Zenas BioPharma, Inc. Common Stock has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, averaging a -18.3% surprise over the last 4. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.

How does ZBIO stock react to earnings?

ZBIO has moved an average of +2.4% the day after earnings over its last 4 reports, finishing higher after 2 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.